PL2190475T3 - Sposoby poprawy właściwości adiuwancyjnych kompozycji szczepionek - Google Patents

Sposoby poprawy właściwości adiuwancyjnych kompozycji szczepionek

Info

Publication number
PL2190475T3
PL2190475T3 PL08875737T PL08875737T PL2190475T3 PL 2190475 T3 PL2190475 T3 PL 2190475T3 PL 08875737 T PL08875737 T PL 08875737T PL 08875737 T PL08875737 T PL 08875737T PL 2190475 T3 PL2190475 T3 PL 2190475T3
Authority
PL
Poland
Prior art keywords
adjuvanticity
enhancing
methods
vaccine compositions
vaccine
Prior art date
Application number
PL08875737T
Other languages
English (en)
Polish (pl)
Inventor
Vincent Serra
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of PL2190475T3 publication Critical patent/PL2190475T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL08875737T 2007-08-29 2008-08-29 Sposoby poprawy właściwości adiuwancyjnych kompozycji szczepionek PL2190475T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29
EP08875737.2A EP2190475B1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions
PCT/IB2008/003016 WO2010023498A1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Publications (1)

Publication Number Publication Date
PL2190475T3 true PL2190475T3 (pl) 2016-04-29

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08875737T PL2190475T3 (pl) 2007-08-29 2008-08-29 Sposoby poprawy właściwości adiuwancyjnych kompozycji szczepionek

Country Status (14)

Country Link
US (1) US8916164B2 (https=)
EP (1) EP2190475B1 (https=)
JP (1) JP5539890B2 (https=)
KR (1) KR101540081B1 (https=)
CN (1) CN101820909A (https=)
AU (1) AU2008360937B9 (https=)
BR (1) BRPI0815846A2 (https=)
ES (1) ES2558157T3 (https=)
HR (1) HRP20151356T1 (https=)
PL (1) PL2190475T3 (https=)
PT (1) PT2190475E (https=)
RU (1) RU2491090C2 (https=)
WO (1) WO2010023498A1 (https=)
ZA (1) ZA201001477B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2537188C2 (ru) 2007-12-05 2014-12-27 Виттисель Композиции и способы для усиления имунного ответа на антигены
EP2842961B1 (en) 2012-04-26 2016-12-14 Riken New carbamate glycolipid and use thereof
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (https=) 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
CZ298895A3 (en) 1993-05-14 1996-04-17 Cytel Corp Compound analogous to sialyl lex, pharmaceutical composition containing thereof and process for preparing lactosammonium salt
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
CA2280130C (en) 1997-02-05 2007-12-18 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
JP3495740B2 (ja) 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
US6492337B1 (en) 1997-12-30 2002-12-10 A+ Science Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
ATE420657T1 (de) * 1999-10-12 2009-01-15 Ca Nat Research Council Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2001252599A1 (en) 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
KR20050043736A (ko) 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
EP1784196B1 (en) 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
CA2578052C (en) 2004-09-03 2013-08-13 The University Of Chicago Methods of activating nkt cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
PT1848813E (pt) 2005-01-28 2013-07-15 Scripps Research Inst Activação de glicolípidos bacterianos de células nkt restritas ao cd1d
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
DK2056842T3 (da) 2006-04-07 2013-01-14 Univ Chicago Modificeret galactosylceramid til behandling af cancerøse sygdomme
CN101426523B (zh) 2006-04-27 2013-03-27 财团法人首尔大学校产学协力财团 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗
EP2040541B1 (en) 2006-06-30 2016-03-23 The Scripps Research Institute Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
RU2537188C2 (ru) 2007-12-05 2014-12-27 Виттисель Композиции и способы для усиления имунного ответа на антигены
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物

Also Published As

Publication number Publication date
US8916164B2 (en) 2014-12-23
RU2010111766A (ru) 2011-10-10
WO2010023498A1 (en) 2010-03-04
EP2190475A1 (en) 2010-06-02
AU2008360937A1 (en) 2010-03-04
RU2491090C2 (ru) 2013-08-27
KR101540081B1 (ko) 2015-07-29
HRP20151356T1 (hr) 2016-01-01
EP2190475B1 (en) 2015-10-28
JP5539890B2 (ja) 2014-07-02
JP2011518760A (ja) 2011-06-30
KR20100072211A (ko) 2010-06-30
US20100285042A1 (en) 2010-11-11
PT2190475E (pt) 2016-02-11
ES2558157T3 (es) 2016-02-02
AU2008360937B9 (en) 2014-02-13
WO2010023498A8 (en) 2010-04-15
ZA201001477B (en) 2010-12-29
BRPI0815846A2 (pt) 2017-05-30
CN101820909A (zh) 2010-09-01
AU2008360937B2 (en) 2014-01-16
AU2008360937A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200904756B (en) Methods of vaccine administration
ZA200808489B (en) Nicotine-carrier vaccine formulation
IL209027A0 (en) Vaccine compositions and uses thereof
GB0810869D0 (en) Vaccine adjuvant composition
GB0711858D0 (en) Vaccine
GB0900772D0 (en) Live vaccine strains of francisella
EP2334332A4 (en) NEW COMPOSITIONS AND NEW ADJUVANTS
IL214127A0 (en) Vaccine compositions
EP2252326A4 (en) VACCINE COMPOSITIONS
EP2498815A4 (en) VACCINE COMPOSITION
GB0805356D0 (en) Vaccine adjuvant composition
GB0710538D0 (en) Vaccine
GB0700135D0 (en) Vaccine
EP2097103A4 (en) VACCINE FORMULATIONS AGAINST INFLUENZA
IL220308A0 (en) Vaccine compositions
ZA201001477B (en) Methods of enhancing adjuvanticity of vaccine compositions
EP2337847A4 (en) ADJUVANTS FOR VACCINES
GB0819079D0 (en) Gypsum based formulations
GB0801122D0 (en) Vaccine composition
GB0606856D0 (en) Vaccine compositions
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0820404D0 (en) Vaccine compositions
GB0601035D0 (en) Method of vaccine preparation
GB0702363D0 (en) Vaccine composition